Clinical manifestations and management of the antiphospholipid syndrome

Abstract

Since the original description of associations between lupus anticoagulant and anti cardiolipin antibodies with thrombosis, fetal loss and thrombocytopenia, several distinct clinical manifestations related to this so-called antiphospholipid syndrome have appeared in the literature. Retrospective studies indicate that long-term treatment with oral anticoagu lants can effectively reduce the chance of recurrent thrombosis. However, data from con trolled prospective studies are urgently needed to enable optimal counselling of patients suffering from this syndrome.

Keywords

antiphospholipid syndrome lupus anticoagulant anticardiolipin antibodies

Get full access to this article

View all access options for this article.

References

Harris EN , Gharavi AE , Hughes Grv. Anti-phospholipid antibodies. Clin Rheum Dis 1985; 11: 591-609.

McNeil HP , Chesterman CN , Krilis SA Immunology and clinical importance of antiphospholipid antibodies . Adv Immunol 1991; 49: 193-280.

Triplett DA , Brandt J. Laboratory identification of the lupus anticoagulant. Br J Haematol 1989; 73: 139-142.

Triplett DA Antiphospholipid antibodies and thrombosis. Arch Pathol Lab Med 1993; 117: 78-88.

Vermylen J. , Arnout J.

Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes?

J Lab Clin Med 1992; 120: 10-12.

Roubey Ras. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other 'antiphospholipid' autoantibodies. Blood 1994; 84: 2854-2867.

Love PE , Santoro SA Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 112: 682-698.

Piette JP et al. Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 1993; 20: 1802-1803.

Derksen Rhwm , Gmelig-Meijling Fhj , de Groot PhG. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. Lupus 1995; in press.

10.

Alarcon-Segovia D. et al. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Sem Arthritis Rheum 1992; 21: 275-286.

11.

Asherson RA , Cervera R. Anticardiolipin antibodies, chronic false-positive tests for syphilis and other antiphospholipid antibodies. In: Wallace DH , Hahn BH (eds). Dubois' lupus erythematosus. Philadelphia: Lea & Febiger, 1993; 233-245.

12.

Cervera R. , Asherson RA , Lie JT

Clinicopathologic correlations of the antiphospholipid syndrome. Sem

Arthritis Rheum 1995; 24: 262-272.

13.

Weinstein C. , Miller MH , Buchanan R. , Littlejohn GO Livedo reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erythematosus. Arch Dermatol 1987; 123: 596-600.

14.

Piette JC , Cacoub P. , Wechsler B.

Renal manifestations of the antiphospholipid syndrome. Sem

Arthritis Rheum 1994; 23: 357-366.

15.

Asherson RA The catastrophic antiphospholipid syndrome. J Rheumatol 1992; 19: 508-512.

16.

Rosove MH , Brewer Pmc. Antiphospholipid thrombosis. Clinical course after the first thrombotic event in 70 patients. Ann Int Med 1992; 117: 303-308.

17.

Derksen RHWM, de Groot PhG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long-term anticoagulation . Ann Rheum Dis 1993; 52: 689-692.

18.

Khamashta MA et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.